FDA Approves RYBREVANT FASPRO™ for Quick, First-Line Lung Cancer Treatment
TL;DR
The FDA approved RYBREVANT FASPRO™, a subcutaneous therapy for EGFR-mutated NSCLC, offering faster, more convenient treatment with fewer reactions compared to IV, and demonstrating improved survival outcomes when combined with LAZCLUZE® in first-line treatment.
Topics:businesshealthcare#egfr-mutations#fda-approval#healthcare#lung-cancer#rybrevant-faspro#subcutaneous-administration
Want the full story? Read the original reporting
Read on Johnson & Johnson